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a  b  s  t  r  a  c  t
The  term drug  reimbursement  describes  the  policy  system  that determines  whether  or  not  a drug  is
entitled  to reimbursement  within  the healthcare  system.  Countries  make  different  decisions  regarding
which  cancer  treatments  to  routinely  provide.  As  a result,  depending  on  the  cancer  drug-indication  and
the country  assessing  it, the  decision  can  be Favourable,  Favourable  with  restrictions  or Non-Favourable.
The  main  objective  of  this  paper  is to  describe  the differences  in  drug  reimbursement  decisions  on cancer
drugs  across  10 European  countries.  This  aim  is achieved  through  testing  a number  of hypotheses  that
can  explain  the  differences  in these  speciﬁc  reimbursement  decisions.  First  of all,  we  collect  data  on
cancer  drug  decisions  for 10  European  countries,  from  2002  to 2014.  Secondly,  the hypotheses  are  tested
on this  database.  The  results  show  that  Social  Health  Insurance  systems  tend to  take  more  Favourable
decisions  than  the  tax-based  systems,  that  cost-effective  drug-indications  have  a higher probability  of
reimbursement  and  that  other  countries  are  more  likely  to make  a  Favourable  decision  if NICE  also
make  it. Moreover,  our  ﬁndings  also  corroborate  that  an economic  evaluation  requirement  reduces  the
number  of Favourable  decisions,  and  that,  during  the  global  ﬁnancial  crisis,  the  number  of Favourable
decisions  has been  reduced,  compared  to Non-Favourable  and  restricted.  To  sum  up, characteristics  of the
drug  reimbursement  system,  drug  particularities  and  the  socioeconomic  situation  are  the  main  factors
determining  the differences  across  countries.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDntroduction
The term drug reimbursement describes the policy system that
etermines whether or not a drug is entitled to reimbursement
ithin the healthcare system. The decisions taken by each health-
are system have an impact on the society, as they determine which
rugs are made available for the patients. These are extremely
mportant decisions, which mix  the clinical and economic evidence
ith ethical judgements. Drug reimbursement encompasses the
ntire process from the submission of a reimbursement request
o the ﬁnal decision. In the last stage of the process, countries
ake different decisions regarding which treatments to routinely
rovide. As a result, depending on the drug-indication and the
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country assessing it, the decision can be Favourable, Favourable
with restrictions or Non-Favourable.
Drug reimbursement has attracted attention from several
authors, due to the different systems that exist. Various compar-
ative analyses have been published recently [1–5], describing the
different national models in the world. Due to these differences,
depending on the drug-indication and the country assessing it,
the ﬁnal decision of reimbursement can differ across countries
[3,6]. There are a number of descriptive and comparative studies
analysing these differences [7–10] and some of them also include
an empirical analyses [11–16]. These last studies are mainly based
on the decisions taken in UK by either the National Institute for
Health and Care Excellence (NICE) or the Scottish Medicine Con-
sortium (SMC). Furthermore, none of these empirical studies have
speciﬁcally analysed decisions on cancer drugs.
In particular, even if the European countries have common
objectives for Health Technology Assessment (HTA) systems, the
process is not homogenous. The operative processes and the organi-
sations work differently across these countries. Our main objective
is to describe the differences in drug reimbursement decisions on
cancer drugs across 10 European countries. We  explore a number
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.


































Decision data by country (sources).
Country Institution/database Data source
England NICE HTA decisions from the NICE
website.
Scotland SMC  HTA decisions from the SMC
website.
Sweden TLV/NLT HTA decisions from the TLV/NLT
website. Validation from the TLV
team.
Belgium RIZIV INAMI HTA decisions from the INAMI
database (online). Validation of the
data and information on MEA  from
the INAMI team.
Portugal INFARMED HTA decisions from INFARMED
database (online). Information on
the MEA  from the INFARMED team.
Poland AOTM Database created by AOTM.
Spain BOTPLUS Database created by EASP and
UCLM from BOTPLUS. Validation of
data by GENESIS.
Germany G-BA HTA decisions from the G-BA
website. Only decisions from 2011
onwards (AMNOG)
Netherlands CVZ/MoH Information on decisions provided
by MoH.
decisions from NICE and SMC, as the other countries do not doc-
ument this information. The non-assessed category collects the
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f hypotheses that can explain the differences in these speciﬁc
eimbursement decisions. The overall hypothesis of this paper is
hat there are differences in cancer drugs decisions across Europe
elated to the characteristics of the drug reimbursement system,
he drug particularities and/or the socioeconomic situation.
The paper is structured as follow. Hypotheses section deﬁnes
he main hypotheses. The third section describes the data on cancer
rugs reimbursement decisions. In Testing the Hypotheses section,
he hypotheses are tested on the cancer database. Finally, these
esults are discussed in the last section.
ypotheses
The overall hypothesis of this paper is that there are differences
n cancer drugs decisions across Europe related to the character-
stics of the drug reimbursement system, the drug particularities
nd/or the socioeconomic situation.
1) The health system implemented in each country has an effect
on the reimbursement decision. This ﬁrst hypothesis is that
the proportion of Favourable decisions (without restrictions)
is higher in Social Health Insurance (SHI) systems than in tax-
based systems. In the latter, the taxes collected are not only to
be used for drug reimbursement, so there is an intrinsic com-
petition for these funds.
2) Countries with higher Public Health Expenditure (PHE) per
capita tend to accept more drugs into the system than the
countries with lower PHE per capita.
3) A cost-effective drug-indication has a higher probability of
reimbursement than a non-cost-effective one. Some authors
have empirically tested this hypothesis during the last decade
[11–16]. Their results were positively related with the previous
statement.
4) NICE is one of the most important HTA agencies around Europe.
Their HTA analyses are considered among the most complete
and strict. Thus, regardless of whether a country’s decision pre-
cedes or follows a NICE decision, other countries will tend to
say yes to drugs for which NICE make a Favourable decision
(without restrictions). Whereas, they will be less likely to say
no when NICE make a Non-Favourable decision.
5) When the reimbursement decision-making requires an eco-
nomic evaluation, the proportion of Favourable decisions is
lower then when it is not required. This requirement differs
across countries.
6) Due to the global ﬁnancial crisis, many austerity measures have
been implemented in Europe. As a consequence, we antic-
ipate proportionately fewer Favourable decisions, and more
restricted and Non-Favourable decisions.
atabase
The sample includes the pharmaceutical technology appraisals
or cancer drugs that have been appraised in 10 European countries
rom January 2002 until November 2014. Our database collects
he drug reimbursement decisions on 161 drug-indications for
he 10 countries selected: Belgium, France, Germany, Netherlands,
oland, Portugal, Spain, Sweden and United Kingdom (Eng-
and and Scotland analysed separately). These countries were
elected because they each have a well-deﬁned HTA process and
ublicly available information on their drug reimbursement pro-
edures.During the last decade, many new cancer drug-indication pairs
ave been appraised. The drugs selected to enter into our study
ere classiﬁed under “malignant disease and immunosuppres-
ion” on the SMC  website. SMC  was the starting point becauseFrance HAS/MoH Database created by the URC-ECO.
Source: own construction.
it appraises all the licensed drugs. However, the SMC list was
validated, checking NICE decisions for any additional cancer drug-
indication. After this process, the number of drug-indications was
161.
Table 1 reports the data source for each country. For some
countries, all drug reimbursement decisions were publicly avail-
able through their websites, but for others, assistance was  required
from the National HTA Agencies or the National Government.
Decision outcome
The decision outcome describes the ﬁnal decision regard-
ing the adoption of the technology: Non-Favourable, Favourable
with restrictions and Favourable. A decision is considered to be
restricted only when it differs from the indication detailed in
the marketing authorisation, for instance, when a positive rec-
ommendation is limited to a sub-group of those identiﬁed in
the marketing authorisation, but it is not considered restricted
when the recommendation is to purchase at the lowest acquisition
cost.
Moreover, in order to capture all possible decisions, the deci-
sion variable has two other categories: non-submission and
non-assessed. The ﬁrst category collects the decisions where the
reimbursement body asked the manufacturer to make a submis-
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Table  3
Decision outcome per country.a
Scotland England Belgium Sweden France
Non-Favourable 38 (23.60%) 34 (21.52%) 4 (2.52%) 5 (3.11%) 7 (4.43%)
Restricted 47 (29.19%) 22 (13.92%) 48 (30.19%) 6 (3.73%) 4 (2.53%)
Favourable 31 (19.25%) 39 (24.68%) 76 (47.80%) 40 (24.84%) 140 (88.61%)
Non-submission 36 (22.36%) 7 (4.43%) 0 (0%) 0 (0%) 0 (0%)
Non-assessed 9 (5.59%) 56 (35.44%) 31 (19.50%) 110 (68.32%) 7 (4.43%)
Total 161 100% 158 100% 159 100% 161 100% 158 100%
Poland Portugal Germany Spain Netherlands
Non-Favourable 27 (16.77%) 7 (4.35%) 1 (0.62%) 0 (0%) 0 (0%)
Restricted 47 (29.19%) 3 (1.86%) 0 (0%) 14 (9.59%) 0 (0%)
Favourable 20 (12.42%) 34 (21.12%) 20 (12.42%) 116 (79.45%) 45 (27.95%)
Non-submission 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Non-assessed 67 (41.61%) 117 (72.67%) 140 (86.96%) 16 (10.96%) 116 (72.05%)




























(ource: own  construction.
a Not all decisions per country sum up to 161, because some decisions predated t
Table 2 summarises the decision outcomes. The database con-
ains 1587 observations, 35% of them were Favourable decisions,
hile only 7.8% were rejected and 12% were restricted. Under the
ategory of non-submission, there are only 43 decisions, account-
ng for 2.71% of the total. The non-assessed category is the highest
ith 41% of observations.
Table 3 presents this information by country. Germany, Portugal,
etherlands and Sweden have a higher number of non-assessed
rugs. Under this category, some data limitations arise. For
nstance, for Germany, data on reimbursement decisions was only
vailable from 2011 (AMNOG) and for Portugal from 2006. As a
esult, for these countries, drug-indications without decision were
ncluded under the non-assessed category. Comparing the other
ountries, France has assessed more cancer drug indications, fol-
owed by Belgium and Spain. Belgium, Poland and Scotland have
he highest rates of restricted decisions.
rug-indications per country
Graph 1 shows the outcome decision in terms of cancer type
er country. When the coloured line reaches the outer circle, it
eans Favourable decision, when it stops in the middle, it means
estricted and when it is blank, it means either rejected or non-
ssessed. The main result of this graph is that the probability of
eimbursement differs across countries. For example, France and
pain tend to accept more cancer drugs, while Poland and Scotland
estricts more decisions than the other countries.
esting the hypotheses
Six hypotheses are proposed to explain differences in drug reim-
ursement decisions across these countries.
1) SHI system vs. tax-based
Half of the countries have a SHI system (Belgium, France,
Germany, Netherlands and Poland) while the other half have
a tax-based system (England, Portugal, Scotland, Spain and
Sweden). The proportion of Favourable decisions (without
restrictions) for SHI systems is hypothesised to be greater than
the proportion for tax-based systems (p1 > p2).
p1 = 69%—Of the 439 SHI system decisions 301 were
Favourable.
p2 = 60%—Of the 436 tax-based system decisions 260 were
Favourable.
A higher proportion of the decisions in SHI systems are
Favourable (p-value = 0.0027).
2) Higher PHE per capita vs. lower PHE per capitaple period (2002).
Germany, Netherlands, France have the higher PHE  per capita,
while Poland, Spain and Portugal have the lower. Table 2 can be
used to test this hypothesis, as it shows the decisions classiﬁed
by country. However, there is not a clear pattern to ratify our
hypothesis. The main problem is data availability. For Germany,
Netherlands and Portugal, there are too few decisions. The only
thing, that can be said, is that Poland restricts more than France.
For both countries, there is enough data but a clear pattern
cannot be determined across countries. As a consequence, this
hypothesis is not supported.
(3) Cost-effective vs. non-cost-effective drug-indications
This hypothesis is tested through the construction of a
variable that determines the cost-effectiveness of each drug-
indication. This variable is created out of the Incremental
Cost-Effectiveness Ratio (ICER) from NICE or SMC  decisions.
Using NICE deﬁnition, it is assumed that a drug is considered
cost-effective, when the drug-indication has an ICER below
£30,000 per QALY. This variable has three categories: cost-
effective, non-cost-effective and no ICER information. Applying
it to our dataset, the hypothesis is tested running a two-sample
proportion test. It compares the proportion of Favourable
decisions (without restrictions) with cost-effective or non-cost-
effective drug-indications (p1 > p2).
p1 = 68%—Of the 296 cost-effective drug-indications 202
were Favourable.
p2 = 59%—Of the 418 non cost-effective drug-indications
246 were Favourable.
There is a higher probability of reimbursement for cost-
effective drug-indications (p-value = 0.0071).
In order to go more on detail, it is important to under-
stand why non-cost-effective drug-indications had a 59% of
Favourable decision. From these decisions, 40.65% were ful-
ﬁlling the end of life criteria implemented by NICE in 2009.
Moreover, 19% of this non-cost-effective/Favourable decisions,
had a MEA  and 24% were orphan drugs. As a result, all these
particularities help explain why  59% of non-cost-effective drug-
indications were still accepted.
(4) NICE vs. other countries’ decisions
Regardless of whether a country’s decision precedes or fol-
lows a NICE decision, other countries will tend to say yes to
drugs for which NICE make a Favourable decision (without
restrictions). Whereas, they will be less likely to say no when
NICE make a Non-Favourable decision. The proportions to be
tested are the following:
p1 = 75%—Of 230 decisions regarding drugs for which NICE
made a Favourable decision 172 were Favourable in the
other countries.





ource: own  construction.
p2 = 33%—Of 223 decisions regarding drugs for which NICE
made a Non-Favourable decision 72 were Non-Favourable
in the other countries.
Thus, other countries are more likely to make a Favourable
decision with respect to drugs for which NICE also make a
Favourable decision, than to say no when NICE says no (p-
value = 0.000).
5) Economic evaluation required vs. non-required
The hypothesis that the proportion of Favourable decisions is
lower when economic evaluation is required.
p1 = 33%—Of 421 decisions requiring an economic evalua-
tion 184 were Favourable.
p2 = 93%—Of 121 decisions not requiring an economic eval-
uation 112 were Favourable.
The probability of a Favourable decision is lower when eco-
nomic evaluation is required (p-value = 0.000).
6) Global ﬁnancial crisis
Decision outcomes are plotted for 2002–2014 in order to
assess the effect of the global ﬁnancial crisis on reimbursement
decisions. Graph 2 shows that from 2008, when the economic
crisis started, there was a drop in the percentage of Favourable
decisions taken in these European countries. This drop was
reﬂected in both, a sharp increase in Non-Favourable decisionsGraph 2. Decision outcomes 2002–2014.
Source: own construction.
and a moderate increase in Favourable but restricted decisions.
Although there is not a systematic pattern for these three cat-
egories over time, it appears that the crisis, and consequent
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iscussion
In this paper, our main objective has been to describe the dif-
erences in drug reimbursement decisions on cancer drugs across
0 European countries. We  have explored a number of hypotheses
hat can explain the differences in these speciﬁc reimbursement
ecisions. As a general result, our overall hypothesis can be cor-
oborated; there exist differences on cancer drug reimbursement
ecisions across the 10 European countries. The results of testing
he six hypotheses showed that the characteristics of the drug reim-
ursement system, the drug particularities and the socioeconomic
ituation are the main factors determining these differences across
ountries.
Comparing our ﬁndings with previous studies [11–16], we also
ound that a cost-effective drug-indication (lower ICER) increases
he probability of reimbursement. However, our analysis has gone
urther by including 10 countries and 875 decisions. The pre-
ious studies focused only on NICE [11–14] or SMC  [16] and
ncluded fewer decisions (e.g. 77 decisions [15]). Another study, by
ernandez-Villafuerte et al. [17], showed that other countries tend
o follow NICE decisions when NICE restricts or rejects the drug,
ut not when it gives a positive recommendation. Even if, in the
ypothesis 4, all decisions are considered (before and after NICE),
ur results differ from this study. This difference may  be related to
he small number of decisions that they are analysing, as they note
17].
In terms of the other ﬁndings, to the best of our knowledge,
here is no existing literature that has statistically tested these
ame hypotheses. Other descriptive and comparative studies ana-
ysed these differences through other perspectives, mainly looking
t each reimbursement system criteria [e.g. 9,10]. The main con-
ribution of this paper, compared to the existing literature, is that
ecisions are collected from 10 countries, that the number of deci-
ions is much higher than the other studies and that it focus only
n one therapeutic area.
Although, the results are satisfactory, during this research we
ncountered a number of limitations. The ﬁrst one related to data
ollection, which was very time consuming and complicated. The
rincipal reason is that not all the countries make their decisions
ublicly available or provide insufﬁcient detail. For instance, Ger-
an  data is only available after 2011, Portugal after 2006 and
pain does not upload their decisions. These issues were overcome
y contacting with national experts who helped us validating our
atabase.
A further limitation concerns the large number of drug-
ndications, categorised as non-assessed (41%). The hypotheses
nly focused on assessed drug-indications. There are two  possi-
le explanations for non-assessment: (1) The manufacturer did not
ake a reimbursement submission in that country, for instance,
he crisis situation might have had a deterrent effect. (2) The MoH
ecided not to look at that particular drug-indication. In addition,
t is possible that a drug-indication was assessed but not reported.
The third important limitation is that each hypothesis was
ested one at a time. It is possible that there is correlation among
hese factors. So, the explanation of these differences is more com-
lex than trying to deﬁne it factor by factor. Another particular
imitation relates to the construction of the variable deﬁning the
ost-effectiveness of each drug-indication. Even if each country has
ts own particularties, for simplicity, NICE or SMC  deﬁnitions were
sed.
The descriptive and comparative analysis done in this paper
as helped to answer our hypotheses, however, this method is not
nough to deﬁne the differences in drug reimbursement decisions
cross countries. These limitations can be overcome by designing
[
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a taxonomy that collects all the characteristics of the drug reim-
bursement system, the drug particularities and the socioeconomic
situation of each country. Applying this classiﬁcation to the cancer
database, we can then specify an econometric model that will be
able to capture all the information and show the main variables
determining the differences. Moreover, it will be important to take
into account that these factors might be correlated among them
and there might be time dependency. This will be done in future
research.
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